Welcome to our dedicated page for Clearmind Medici SEC filings (Ticker: CMND), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clearmind Medicine Inc.'s SEC filings document foreign private issuer reports for a clinical-stage biotech developing non-hallucinogenic, neuroplastogen-derived psychedelic therapeutics. Form 6-K reports furnish press releases on CMND-100, MEAI-based Alcohol Use Disorder clinical development, European patent activity for PTSD compounds, and communications tied to FDA regulatory pathways.
The filings also record capital-structure matters, including securities purchase agreements, convertible promissory notes, conversions into common shares and amendments to financing capacity. Governance disclosures cover board composition, committee assignments and Nasdaq independence determinations, while incorporated registration statements on Form F-3 and Form S-8 connect current reports to the company's securities registration record.
Clearmind Medicine Inc. amended a Schedule 13G/A reporting that L.I.A. Pure Capital Ltd. holds five percent or less of the company’s common shares as of 03/31/2026. The filing identifies the reporting person, its Israel address, and CUSIP 185053402.
Clearmind Medicine Inc. receiving a Schedule 13G/A amendment from Capitalink Ltd. reports ownership of 5 percent or less of the class of Common Shares (CUSIP 185053402).
The amendment (Amendment No. 3) lists Capitalink Ltd., an Israel entity, as the reporting person and incorporates cover-page items for detailed voting and dispositive power. The filing is signed by Lavi Krasney as CEO on 05/15/2026.
Clearmind Medicine Inc. filed a Form 6-K highlighting a clinical milestone in its Phase I/IIa trial of CMND-100 (MEAI) for moderate to severe alcohol use disorder. The company has now treated 20 participants across all cohorts, after dosing two additional patients in the fourth cohort.
The fourth cohort is receiving a higher 160 mg dose of CMND-100, following a positive recommendation from the Data and Safety Monitoring Board and successful completion of the third cohort in April 2026. The first three cohorts, totaling 18 participants, met the primary safety endpoint with no serious adverse events reported, supporting continued dose escalation.
The ongoing FDA-approved trial is a multinational, multicenter study assessing safety, tolerability, pharmacokinetics and preliminary efficacy at institutions including Yale School of Medicine, Johns Hopkins University School of Medicine, Tel Aviv Sourasky Medical Center and Hadassah Medical Center. Clearmind describes itself as a clinical-stage neuroplastogens biotech with 19 patent families and 31 granted patents, focused on non-hallucinogenic treatments for under-served conditions such as alcohol use disorder.
Clearmind Medicine Inc. has filed a European patent application covering novel psychedelic compounds aimed at treating Post-Traumatic Stress Disorder (PTSD) and other mental health disorders. The application is part of its exclusive worldwide licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem.
Clearmind holds exclusive global rights under this agreement to develop, manufacture, and commercialize Yissum-derived compounds and is responsible for advancing them through regulatory pathways. The company describes itself as a clinical-stage biotech focused on non-hallucinogenic, second generation, neuroplastogen-derived therapeutics for under-treated conditions such as alcohol use disorder.
The PTSD treatment market is cited at about $18.5 billion in 2025, projected to reach $30.2 billion by 2035, a 5.0% CAGR, highlighting the commercial potential of effective therapies. Clearmind’s intellectual property portfolio currently consists of nineteen patent families, including thirty-one granted patents, and the company plans to pursue additional protections where warranted.
Clearmind Medicine Inc. files a Form F-3 to register for resale up to 22,626,988 common shares that are issued or issuable upon conversion of convertible promissory notes held by institutional investors (the CLA Investors). The registered shares are calculated assuming conversion of up to $10.0M principal plus $3.576M accrued interest at an assumed conversion price of $0.60 per share.
The company has received $8.15M in gross proceeds from Promissory Notes to date and may receive up to an additional $10.0M of gross proceeds under the SPAs. Conversion terms provide that the conversion price is the lower of a $40.40 fixed price or 88% of the 20-day VWAP, subject to a $0.60 Floor Price (amended). CLA Investor conversions are limited so no single CLA Investor exceeds 4.99% beneficial ownership following conversion.
Clearmind Medicine Inc. amended its previously announced securities purchase agreements for convertible promissory notes so that, as of April 30, 2026, $10,000,000 of capacity remains available for future issuances of these notes. This preserves access to additional financing through convertible debt instruments agreed with existing investors.
The company also reported governance changes. On April 26, 2026, board chair Amitay Weiss resigned, stating his departure did not arise from any disagreement with the company or its management. On April 27, 2026, the board appointed Hila Kiron-Revach as chairperson and added Asaf Itzhaik to the compensation and nominating and corporate governance committees. The audit, compensation, and nominating committees were reconstituted, and the board designated Kiron-Revach, Yehonatan Shachar, and Itzhaik as independent under Nasdaq listing rules.
Clearmind Medicine Inc. furnished a report describing its evaluation of lead candidate CMND-100 (MEAI) for potential U.S. FDA Breakthrough Therapy Designation to treat Alcohol Use Disorder. The company cites positive results so far from its ongoing FDA-approved Phase I/IIa clinical trial in this indication.
Clearmind develops non-hallucinogenic, second-generation neuroplastogen-derived therapeutics for under-treated conditions and holds a growing patent portfolio. The company stresses that it has not yet submitted a Breakthrough Therapy Designation request for MEAI and that the FDA has not granted any such designation.
Clearmind Medicine Inc. reports new activity under its previously announced convertible note financing and a rapid conversion into equity. The company agreed with its CLA Investors to issue and sell convertible promissory notes with an aggregate principal amount of $2,700,000, for a cash purchase price equal to 90% of principal, or $2,430,000. On April 21, 2026, the CLA Investors converted an aggregate of $2,680,029.60 under the notes into 4,466,716 common shares in accordance with the note terms.
Clearmind Medicine Inc. is drawing additional funding under previously announced securities purchase agreements. The company agreed with existing CLA Investors to issue and sell convertible promissory notes with an aggregate principal amount of $2,700,000. These notes will be purchased for cash equal to 90% of principal, or $2,430,000, and are part of a larger facility of up to $10,000,000 in convertible promissory notes. The transaction is expected to close on or about April 21, 2026, and this report is incorporated by reference into Clearmind’s existing Form F-3 and Form S-8 registration statements.
Clearmind Medicine Inc. is drawing additional funding under previously announced securities purchase agreements. The company agreed with existing CLA Investors to issue and sell convertible promissory notes with an aggregate principal amount of $2,700,000. These notes will be purchased for cash equal to 90% of principal, or $2,430,000, and are part of a larger facility of up to $10,000,000 in convertible promissory notes. The transaction is expected to close on or about April 21, 2026, and this report is incorporated by reference into Clearmind’s existing Form F-3 and Form S-8 registration statements.